The Procter Gamble Company

Thomas L Cupps

Sophie Eva Bogdan

Russell James Sheldon

Raymond Todd Henry

Jeffrey Joseph Ares

William Lee Seibel

Neil Gregory Almstead

Biswanath De

Michael G Natchus

Stanislaw Pikul

Joseph H Gardner

Yetunde Olabisi Taiwo

Gerald B Kasting

Peter J Maurer

Kelly Lynn McDow-Dunham

Rimma Sandler Bradley

Joel I Shulman

Thomas W Gibson

Richard S Echler

Brian Lee Buckwalter

Timothy P O'Neill

Roy Lee Dobson

Sheri Ann Gilbert

Nick Nikolaides

Michael Gazda

Elizabeth F Berman

Charles Andrew Iii Cruze

Glen E Mieling

5-(2-imidazolinylamino)-benzimidazole derivatives, their preparation and their use as .alpha.-adrenoceptor agonists with improved metabolic stability

Guanidinylamino heterocycle compounds useful as &agr;-2 adrenoceptor agonists

7-(2-imidazolinylamino) quinoline compounds useful as alpha-2 adrenoceptor agonists

Diheterocyclic metalloprotease inhibitors

Guanidinyl heterocycle compounds useful as alpha-2 adrenoceptor agonists

This invention involves compounds having the following structure

Guanidinylamino heterocycle compounds useful as alpha-2 adrenoceptor agonists

This invention involves compounds having the following structure:

This invention involves compounds having the structure (I) as described in the claims, and enantiomers,optical isomers, stereoisomers, diastereomers, tautomers, addition salts, biohydrolyzable amides and esters thereof, as well as pharmaceutical compositions comprising such noved compounds. The invention also relates to the use of such compounds for preventing or treating disorders modulated by alpha-2 adrenoceptors.

The invention provides compounds of formula ##STR1## as described in the claims, or an optical isomer, diastereomer or enantiomer thereof, or a pharmaceutically-acceptable salt, or biohydrolyzable amide, ester, or imide thereof are useful as inhibitors of metalloproteases. Also disclosed are pharmaceutical compositions and methods of treating diseases, disorders and conditions characterized by metalloprotease activity using these compounds or the pharmaceutical compositions containing them.

1,5-heterocyclic metalloprotease inhibitors

This invention involves involves the use of compounds having the following structure: ##STR1## wherein: (a) R is unsubstituted C.sub.1 -C.sub.3 alkanyl or alkenyl; and

7-(2-imidazolinylamino)quinoline compounds useful as alpha-2

The subject invention relates to compounds having the structure: ##STR1## as defined in the claims, and to pharmaceutical compositions containing such compounds, and the use of such compounds for preventing or treating of disorders modulated by alpha-2 adrenoceptors.

6-(2-imidazolinylamino) quinolines useful as alpha-2 adrenoceptor

The subject invention relates to compounds having the structure: ##STR1## wherein: (a) R is unsubstituted C.sub.1 -C.sub.3 alkanyl or alkenyl;

6-(2-Imidazolinylamino) quinoline compounds useful as alpha-2

The subject invention involves methods of treating nasal congestion comprising administration, to a human or lower animal in need of such treatment of a safe and effective amount of a compound having the following structure: ##STR1## wherein: (a) R is unsubstituted C.sub.1 -C.sub.3 alkanyl or alkenyl; and

The subject invention involves compounds having the following structure: ##STR1## wherein: (a) R is unsubstituted C.sub.1 -C.sub.3 alkanyl or alkenyl;

5-(2-imidazolinylamino)benzimidazole compounds useful as

Growing community of inventors

Oxford, OH, United States of America

Thomas L Cupps